Key result
Genetically predicted nonalcoholic fatty liver disease was causally associated with decreased appendicular lean mass (OR 0.98) and right-hand grip strength, indicating an increased risk of sarcopenia.
Why the study?
Studies have shown a broad association between liver disease and sarcopenia, but the link remains unclear.
Does nonalcoholic fatty liver disease have a causal genetic relationship with sarcopenia?
Observational (n=461,089)
Does nonalcoholic fatty liver disease have a causal genetic relationship with sarcopenia?
Mendelian randomization provides evidence of a causal genetic relationship between NAFLD and sarcopenia, identifying 153 pleiotropic genes as potential therapeutic targets.
Answers are grounded in this paper and cite their sources.
May indicate NAFLD-sarcopenia link; hypothesis-generating and requires prospective validation before clinical adoption.
With the aging of the population, sarcopenia has become more common. Studies have shown a broad association between liver disease and sarcopenia. However, this link remains unclear. Our study explored the link between NAFLD and sarcopenia and predicting the pathogenesis. To begin, we investigated the causal relationship and genetic correlation between them using MR and LDSC. Second, each GWAS was annotated by MAGMA. The annotated genes were analyzed for pleiotropy using the PLACO approach. Finally, functional analysis was conducted on the identified pleiotropic genes. We observed a significant genetic correlation between NAFLD and sarcopenia. Subsequently, we conducted gene-level pleiotropy analysis using PLACO and identified a total of 153 genes with pleiotropic effects. Functional analysis revealed enrichment of these genes in various tissues, including pancreas, liver, heart, blood, brain, and muscle, with involvement in cellular regulation, intracellular function, and antigen response. Moreover, our MR analysis provided evidence of a causal relationship between NAFLD and sarcopenia. Our study has discovered the genetic and causal relationships between NAFLD and sarcopenia, providing further insights into their pathophysiological mechanisms. The identification of pleiotropic genes also offers potential targets for future drug therapies aimed at controlling or treating NAFLD and sarcopenia.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2024) conducted an observational in Nonalcoholic fatty liver disease (NAFLD) and sarcopenia (n=461,089). Genetically predicted nonalcoholic fatty liver disease (NAFLD) vs. Control (no NAFLD) was evaluated on Appendicular lean mass (ALM) (OR 0.98, 95% CI 0.97-0.99, p=1.97E-4). Genetically predicted nonalcoholic fatty liver disease was causally associated with decreased appendicular lean mass (OR 0.98) and right-hand grip strength, indicating an increased risk of sarcopenia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: